Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second write-up, the regulatory agency flagged issues ranging from unqualified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback